Trou­bled Voy­ager’s gene ther­a­py re­launch gets a boost with $630M Pfiz­er deal

It was spring, the pan­dem­ic seemed in re­treat, pa­trons were fill­ing Boston’s bars again and, in Cam­bridge, Voy­ager Ther­a­peu­tics was in trou­ble.

The Third Rock-found­ed biotech emerged in 2014 as one of the first of the flashy new gene ther­a­py com­pa­nies, promis­ing one-time treat­ments for com­mon dev­as­tat­ing con­di­tions like Alzheimer’s. It was one of the first to de­liv­er re­sults, too: By 2017, its Parkin­son’s treat­ment had im­proved mo­tor func­tion in 10 pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER